Search - tctmd.com

Displaying 341 - 360 of 788

Sort: Relevancy | Date

News Daily News

《2014年NSTE-ACS管理指南》有了新的标题和着重点

September 30, 2014

News Daily News

Las Directrices 2014 para el Manejo de SCASEST tienen un Nuevo Nombre y Objetivo

September 30, 2014

News Daily News

2014 Guideline for NSTE-ACS Management Has New Name, Focus

September 30, 2014

News Conference News TCT 2014

Long-term Outcomes Worse for Patients with Coronary Artery Aneurysm After DES Implantation

Yael L. Maxwell

September 19, 2014

News Conference News TCT 2014

Real-World Data Show Correlation Between Post-PCI Angina, Resource Utilization

September 18, 2014

News Conference News TCT 2014

Microvascular Dysfunction Prevalent in Patients with Chest Pain, Non-Obstructive CAD

September 18, 2014

Presentation TCT 2014

Absorb III/IV: Angina and Ischemia Hypotheses

Presenter: Mitchell W. Krucoff, John A. Ormiston, Robert-Jan van Geuns, Gregg W. Stone

September 16, 2014

Presentation TCT 2014

Analysis of Quality of Life Decrements Associated with Changes in Angina Status in the ABSORB II Trial: First Randomized Comparison Between the Absorb? Everolimus Eluting___

Presenter: Bernard Chevalier

September 16, 2014

News Industry News

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

September 16, 2014

News Industry News

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

September 16, 2014

Presentation TCT 2014

TCT 102: Incidence of Angina and Chest Pain Following Percutaneous Coronary Intervention: A Retrospective Analysis Using Administrative Claims Data in the United States

Presenter: David P. Faxon, Ori Ben-Yehuda

September 15, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Industry News

New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients with Second-Generation Drug-Eluting Stents

September 15, 2014

News Industry News

Neovasc Reducer™ Featured in Live Case Session at TCT 2014 Scientific Symposium

September 15, 2014

News Industry News

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

September 15, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Industry News

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

September 14, 2014

News Conference News TCT 2014

ABSORB EXTEND: BVS Safe Out to 3 Years

September 14, 2014

Presentation TCT 2014

Stable Angina: PCI vs CABG vs OMT

Presenter: J. Jeffrey Marshall, Thomas M Tu

September 13, 2014

Advertisement

《2014年NSTE-ACS管理指南》有了新的标题和着重点

Las Directrices 2014 para el Manejo de SCASEST tienen un Nuevo Nombre y Objetivo

2014 Guideline for NSTE-ACS Management Has New Name, Focus

Long-term Outcomes Worse for Patients with Coronary Artery Aneurysm After DES Implantation

Real-World Data Show Correlation Between Post-PCI Angina, Resource Utilization

Microvascular Dysfunction Prevalent in Patients with Chest Pain, Non-Obstructive CAD

Absorb III/IV: Angina and Ischemia Hypotheses

Analysis of Quality of Life Decrements Associated with Changes in Angina Status in the ABSORB II Trial: First Randomized Comparison Between the Absorb? Everolimus Eluting___

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

TCT 102: Incidence of Angina and Chest Pain Following Percutaneous Coronary Intervention: A Retrospective Analysis Using Administrative Claims Data in the United States

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients with Second-Generation Drug-Eluting Stents

Neovasc Reducer™ Featured in Live Case Session at TCT 2014 Scientific Symposium

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

ABSORB EXTEND: BVS Safe Out to 3 Years

Stable Angina: PCI vs CABG vs OMT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content